Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 35

Results For "NAL"

6627 News Found

Zydus receives final approval from the USFDA for Acyclovir Cream
Drug Approval | March 03, 2023

Zydus receives final approval from the USFDA for Acyclovir Cream

he product will be launched shortly in the US market.


Zydus receives final approval from the USFDA for Apixaban Tablets
Drug Approval | March 01, 2023

Zydus receives final approval from the USFDA for Apixaban Tablets

Apixaban Tablets, 2.5 mg and 5 mg had annual sales of USD 18,876 mn in the United States (IQVIA MAT Dec. 2022).


Zydus receives final approval from the USFDA for Hydrochlorothiazide Tablets
Drug Approval | March 01, 2023

Zydus receives final approval from the USFDA for Hydrochlorothiazide Tablets

This combination medicine is used to treat high blood pressure (hypertension).


Agilent announces cell analysis workflow automation for immuno-oncology, virology, and vaccine development markets
Digitisation | February 27, 2023

Agilent announces cell analysis workflow automation for immuno-oncology, virology, and vaccine development markets

New workflow integrates the xCELLigence RTCA HT with the BioTek BioSpa 8 Automated Incubator


National Health Authority facilitating Quick OPD registration in 365 hospitals
Policy | February 24, 2023

National Health Authority facilitating Quick OPD registration in 365 hospitals

More than 5 lakh patients availed the benefit of queue-less OPD registration using this service


Moderna and Merck announce investigational personalized cancer vaccine mRNA-4157/V940
Drug Approval | February 23, 2023

Moderna and Merck announce investigational personalized cancer vaccine mRNA-4157/V940

Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial


Aji Bio-Pharma develops highly functional ancestral RNA ligase
Biotech | February 23, 2023

Aji Bio-Pharma develops highly functional ancestral RNA ligase

This artificial RNA ligase has higher thermostability than natural RNA ligase


USFDA accepts biologics license application for Pfizer’s respiratory syncytial virus maternal vaccine candidate for priority review
Drug Approval | February 22, 2023

USFDA accepts biologics license application for Pfizer’s respiratory syncytial virus maternal vaccine candidate for priority review

This action follows the recent acceptance of the Marketing Authorization Application (MAA) for Pfizer’s RSV vaccine candidate by the European Medicines Agency